ARC Launches Clinical Fellowship Program to Advance Amyloidosis Care [Yahoo! Finance]
Ionis Pharmaceuticals, Inc. (IONS)
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ionispharma.com
Company Research
Source: Yahoo! Finance
Program, designed to enhance the education and development of the next generation of amyloidosis specialists. This initiative aims to increase the pool of physicians equipped to provide expert care and lead scientific advancements in the diagnosis and management of this complex and rare disease. The Clinical Fellowship Program will provide funding for up to eight one-year fellowships, to established amyloidosis centers across the United States . The program is dedicated to training promising MD fellowship applicants, enhancing their skills in multidisciplinary collaboration, research participation, and health equity. "This program represents a significant step forward in building a robust workforce capable of addressing the complex challenges of amyloidosis," said Dr. Vaishali Sanchorawala , Director of the Amyloidosis Center, Boston University Chobanian and Avedisian School of Medicine. "By fostering innovation and a comprehensive training experience, we can significantly improve
Show less
Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IONS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IONS alerts
High impacting Ionis Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
IONS
News
- Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal [Yahoo! Finance]Yahoo! Finance
- Ionis and Ono announce global license agreement for sapablursen in polycythemia veraBusiness Wire
- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target lowered by analysts at JPMorgan Chase & Co. from $51.00 to $47.00. They now have a "neutral" rating on the stock.MarketBeat
- WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathyBusiness Wire
- Ionis to present at upcoming investor conferences [Yahoo! Finance]Yahoo! Finance
IONS
Earnings
- 2/19/25 - Beat
IONS
Sec Filings
- 3/12/25 - Form 8-K
- 3/11/25 - Form 144
- 3/4/25 - Form 4
- IONS's page on the SEC website